Can we improve the clinical risk score? the prognostic value of p53, Ki-67 and thymidylate synthase in patients undergoing radical resection of colorectal liver metastases

HPB

Volumn 16, Issue 3, 2014, Pages 235-242

  Ivanecz, Arpad ^a   Kavalar, Rajko ^a   Palfy, Miroslav ^a   Pivec, Vid ^a   Sremec, Marko ^a   Horvat, Matjaž ^a   Potrč, Stojan ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN; OXALIPLATIN; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL INDICATOR; CLINICAL RISK SCORE; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PROTEIN EXPRESSION; RADICAL RESECTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TISSUE MICROARRAY;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THYMIDYLATE SYNTHASE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894499151     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12089     Document Type: Article

References (40)

1. Pulitanò C, Castillo F, Aldrighetti L, Bodingbauer M, Parks RW, Ferla G, et al. (2010) What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB 12: 244-249.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25: 4575-4580.
3. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. (2007) Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246: 806-814.
4. Rees M, Tekkis PP, Welsh FKS, O'Rourke T, John TG,. (2008) Evaluation of longterm survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247: 125-135.
5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-321.
6. Ivanecz A, Potrc S, Horvat M, Jagric T, Gadzijev E,. (2009) The validity of clinical risk score for patients undergoing liver resection for colorectal metastases. Hepatogastroenterology 56: 1452-1458.
7. Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, et al. (2009) Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 16: 3279-3288.
8. Pawlik TM, Choti MA,. (2006) Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Colorectal Cancer Rep 2: 85-93.
9. Munro AJ, Lain S, Lane DP,. (2005) p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92: 434-444.
10. Scholzen T, Gerdes J,. (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322.
11. Lentz F, Tran A, Rey E, Pons G, Tréluyer JM,. (2005) Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer. Am J Pharmacogenomics 5: 21-33.
12. De Jong KP, Gouw ASH, Peeters PMJG, Bulthuis M, Menkema L, Porte RJ, et al. (2005) p53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11: 4067-4073.
13. Hamilton SR, Aaltonen LA, eds. (2000) WHO Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press.
14. Packeisen J, Buerger H, Krech R, Boecker W,. (2002) Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol 55: 613-615.
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4: 844-847.
16. D'Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L, et al. (2011) Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod Pathol 24: 1221-1228.
17. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, et al. (2010) Is preoperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252: 774-787.
18. Andres A, Toso C, Adam R, Barroso E, Hubert C, Capussotti L, et al. (2012) A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases. Ann Surg 256: 772-779.
19. Jamal MH, Hassanain M, Chaudhury P, Tran TT, Wong S, Yousef Y, et al. (2012) Stage hepatectomy for bilobar colorectal hepatic metastases. HPB 14: 782-789.
20. Jones C, Taylor MA, McWilliams B,. (2013) The role of cetuximab as first-line treatment of colorectal liver metastases. HPB 15: 11-17.
21. Menon AG, Tollenaar R, van de, Velde C, Putter H, Janssen-van Rhijn CM, Keijzer R, et al. (2004) p53 and HLA class-I expression are not downregulated in colorectal cancer liver metastases. Clin Exp Metastasis 21: 79-85.
22. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, et al. (2003) Thymidylate synthase expression in hepatic tumours is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 21: 406-412.
23. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al. (1996) p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696-2701.
24. Heisterkamp J, van Bommel J, Hop WC, Tilanus HW, Zondervan PE, Ijzermans JNM,. (1999) p53 overexpression in colorectal metastases confined to the liver and outcome of liver resection. Hepatogastroenterology 46: 3109-3114.
25. Crowe PJ, Phil D, Yang JL, Berney CR, Erskine C, Ham JM, et al. (2001) Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 25: 996-1001.
26. Tanaka K, Shimada H, Miura M, Fujii Y, Yamaguchi S, Endo I, et al. (2004) Metastatic tumour doubling time: most important prehepatectomy predictor of survival and non-recurrence of hepatic colorectal cancer metastasis. World J Surg 28: 263-270.
27. Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. (2008) A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology 75: 32-41.
28. Backus HHJ, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, et al. (2002) Differential expression of cell cycle and apoptosis-related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55: 206-211.
29. Bosari S, Viale G,. (1995) The clinical significance of p53 aberrations in human tumours. Virchows Arch 427: 229-241.
30. Yang Y, Forslund A, Remotti H, Lönroth C, Andersson M, Brevinge H, et al. (2001) p53 mutations in primary tumours and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91: 727-736.
31. Molleví DG, Serrano T, Ginestà MM, Valls J, Torras J, Navarro M, et al. (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 28: 1241-1246.
32. Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, et al. (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832-2843.
33. Saw RP, Koorey D, Painter D, Gallagher PJ, Solomon MJ,. (2002) p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 89: 1409-1415.
34. Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, et al. (2001) Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 182: 81-88.
35. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, et al. (2001) Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27: 80-87.
36. Smith DL, Soria JC, Morat L, Yang Q, Sabatier L, Liu DD, et al. (2004) Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 11: 45-51.
37. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, et al. (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17: 572-578.
38. Anjomshoaa A, Nasri S, Humar B, McCall JL, Chatterjee A, Yoon HS, et al. (2009) Slow proliferation as a biological feature of colorectal cancer metastasis. Br J Cancer 101: 822-828.
39. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, et al. (2002) Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 38: 527-534.
40. Lassmann S, Tang L, Capanu M, Brabletz T, Schöpflin A, Hausen AZ, et al. (2007) Predictive molecular markers for colorectal cancer patients with resected liver metastases and adjuvant chemotherapy. Gastroenterology 133: 1831-1839.